{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:19:41Z","timestamp":1787843981875,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"DOI":"10.7759\/cureus.115294","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:42:34Z","timestamp":1787841754000},"source":"Crossref","is-referenced-by-count":0,"title":["Heart Failure With Preserved Ejection Fraction: A Practical, Stepwise Guide to Evidence-Based Therapy in 2026"],"prefix":"10.7759","author":[{"given":"M. Nour","family":"Chabalout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alazzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaswinder Pal Singh","family":"Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon SD","year":"2024","unstructured":"Solomon SD, McMurray JJ, Vaduganathan M, et al.. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024, 391:1475-85. 10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04037-3","article-title":"Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction","volume":"32","author":"Vaduganathan M","year":"2026","unstructured":"Vaduganathan M, Claggett BL, Chatur S, et al.. Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction. Nat Med. 2026, 32:325-31. 10.1038\/s41591-025-04037-3","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell P","year":"2024","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024, 403:1083-1092. 10.1016\/S0140-6736(23)02756-3","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.06.018","article-title":"Management of heart failure with preserved ejection fraction: 2026 ACC expert consensus decision pathway: a report of the American College of Cardiology Solution Set Oversight Committee","author":"Kittleson MM","year":"2026","unstructured":"Kittleson MM, Panjrath GS, Bates K, Breathett KK, Dixon DL, Januzzi JL Jr, Mohammed SF. Management of heart failure with preserved ejection fraction: 2026 ACC expert consensus decision pathway: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2026, 10.1016\/j.jacc.2026.06.018","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022, 79:e263-421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan M","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al.. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022, 400:757-767. 10.1016\/S0140-6736(22)01429-5","journal-title":"Lancet"},{"key":"ref9","unstructured":"Food and Drug Administration (FDA). KERENDIA (finerenone) tablets, for oral use (prescribing information). (2025). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215341s009lbl.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref12","unstructured":"Food and Drug Administration (FDA). JARDIANCE\u00ae (empagliflozin tablets), for oral use (prescribing information). (2025). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/204629s063lbl.pdf."},{"key":"ref13","unstructured":"Food and Drug Administration (FDA). FARXIGA\u00ae (dapagliflozin) tablets, for oral use (prescribing information). (2023). Accessed. Revised: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202293s026lbl.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial","volume":"329","author":"Mentz RJ","year":"2023","unstructured":"Mentz RJ, Anstrom KJ, Eisenstein EL, et al.. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023, 329:214-23. 10.1001\/jama.2022.23924","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, et al.. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024, 404:949-961. 10.1016\/S0140-6736(24)01643-X","journal-title":"Lancet"},{"key":"ref16","unstructured":"Food and Drug Administration (FDA). WEGOVY (semaglutide) injection, for subcutaneous use (prescribing information). (2025). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf."},{"key":"ref17","unstructured":"Food and Drug Administration (FDA). ZEPBOUND\u00ae (tirzepatide) Injection, for subcutaneous use (prescribing information). (2024). Accessed. Revised: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s013lbl.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt B","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al.. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014, 370:1383-92. 10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland JG","year":"2018","unstructured":"Cleland JG, Bunting KV, Flather MD, et al.. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018, 39:26-35. 10.1093\/eurheartj\/ehx564","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/528989-heart-failure-with-preserved-ejection-fraction-a-practical-stepwise-guide-to-evidence-based-therapy-in-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:42:35Z","timestamp":1787841755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/528989-heart-failure-with-preserved-ejection-fraction-a-practical-stepwise-guide-to-evidence-based-therapy-in-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.115294","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}